Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res. 2008 Oct 15; 68(20):8369-76.
View in:
PubMed
subject areas
Animals
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Antimetabolites, Antineoplastic
Cell Line, Tumor
Cell Line, Tumor
Deoxycytidine
Deoxycytidine
Diffusion Magnetic Resonance Imaging
Diffusion Magnetic Resonance Imaging
Female
Female
Humans
Humans
Mice
Mice
Pancreatic Neoplasms
Pancreatic Neoplasms
Receptors, TNF-Related Apoptosis-Inducing Ligand
Receptors, TNF-Related Apoptosis-Inducing Ligand
Tissue Distribution
Tissue Distribution
Tomography, Emission-Computed, Single-Photon
Tomography, Emission-Computed, Single-Photon
Xenograft Model Antitumor Assays
Xenograft Model Antitumor Assays
authors with profiles
Lacey R McNally